| Name | Title | Contact Details |
|---|
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
Higi began with a simple idea: being healthy should be simple, fun and rewarding. By making the process convenient and automated, we want to provide the most frictionless method for you to play an active role in your personal health and wellness. We are firm believers that understanding and tracking your data is the key first step to achieving your wellness goals. From your basic vitals to physical activity and nutrition, we are building solutions to help you do just that.
Greer Laboratories Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Greer Laboratories Inc. is based in Lenoir, NC. You can find more information on Greer Laboratories Inc. at www.greerlabs.com
Touchstone Health HMO is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.